Phase 4 N=142 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Renal Cell Carcinoma
Primary: PFS (Progression-Free Survival) — 27.71 Weeks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,349 Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
Renal Cell Carcinoma
Primary: Duration of Sunitinib and Pazopanib Treatment in Participants — 171; 114.5 days
Phase 2 N=94 Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 17 percentage of participants
Phase 2 N=134 Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Progression-free Survival (PFS) - All Participants — 7.4 months
Phase 2 N=41 Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: 4-month Progression-Free Survival Rate — 65 percentage of participants — p=0.081
Phase 2 N=80 Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
Kidney Cancer
Primary: Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease…
Phase 2 N=50 Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: Progression Free Survival (PFS) — 11 months
Phase 1 N=25 Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
Renal Cell Cancer
Primary: Metabolic Response — 5 participants
Phase 2 N=55 Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Overall Response Rate — 27 percentage of patients
Phase 2 N=57 Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma
Primary: To Evaluate the Efficacy of Combining Everolimus and Bevacizumab in Patients With Advanced RCC of Non-clear Cell Histology — 78 percent of participants
Phase 2 N=10 Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
Kidney Cancer
Primary: Progression Free Survival (PFS) of Carfilzomib Therapy in Participants With Refractory Or Intolerant to Prior Therapy — 1.8 Months
Phase 2 N=25 SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients
Kidney Cancer Metastatic · Kidney Cancer · Kidney Cancer, Stage IV
Primary: Number of Participants With Treatment-related Adverse Events Grade 3 or Higher as Assessed by CTCAE v4.0 — 9 Participants
Phase 2 N=34 Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: Progression Free Survival (PFS) — 5.5 Months
Phase 3 N=435 Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
Carcinoma, Renal Cell
Primary: Progression-free Survival — 9.2; 4.2 months — p=.0000001
Phase 2 N=25 Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Progression-free Survival — 12 Weeks
Phase 2 N=65 Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Advanced Non-Clear Cell Kidney Cancer
Primary: Best Overall Response Rate — 33 percentage of participants
Phase 2 N=52 Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
Kidney Neoplasms
Primary: Percentage of Participants With Objective Response (OR) — 44.2 Percentage of participants
Phase 2 N=39 Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma · Renal Cell Carcinoma With Sarcomatoid Features
Primary: Response Rate by Solid Tumor Response Criteria (RECIST) — 16 Percentage of Participants
N/A N=448 SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Number of Participants With Categorical Best Overall Response — 13; 130; 120; 58 Participants
Phase 2 N=127 Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
Locally Advanced or Metastatic Renal Cell Carcinoma
Primary: Cohort A: Objective Response Rate (ORR) Assessed by Independent Central Review — 40.5 percentage of participants
Phase 2 N=30 Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours
Renal Cell Carcinoma
Primary: Toxicities Measured Using CTCAE Version 4.03 — 4 participants with G3 TRAEs
Phase 2 N=21 Neoadjuvant Pazopanib in Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Response Rate — 8 Participants
Phase 3 N=886 A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
Renal Cell Cancer
Primary: Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive Participants — 13.8; 7.2 Months…
Phase 2 N=164 Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Primary: 1-year Progression Free Survival (PFS) Rate for ccRCC Patients — 34.6; 53.8; 33.3; 75 Percentage of participants
Phase 2 N=25 Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
Renal Cell Carcinoma · Renal Cancer
Primary: Difference in Median Progression Free Survival Time Between Favorable and Unfavorable Biomarker Group
Phase 2 N=71 Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Percentage Change From Baseline in Tumour Size at 12 Weeks — -19.47; 19.65 Percentage change from baseline
Phase 2 N=305 A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Percentage of Participants With Disease Progression Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Via Independent Review Committee (IRC)…
Phase 2 N=108 Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
Advanced Non-clear Cell Renal Cell Carcinoma
Primary: Anti-tumor Activity as Measured by Median Progression Free Survival Time — 5.6; 8.3 Months — p=0.157
Phase 2 N=18 Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma · Fumarate Hydratase Deficient Renal Cell Carcinoma · Succinate Dehydrogenase Deficient Renal Cell Carcinoma
Primary: the Objective Response Rate (ORR) — 0; 0; 10; 8 Participants
Phase 2 N=106 A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
Carcinoma, Renal Cell
Primary: Number of Subjects With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST) — 35 participants